Rock Springs Capital Management LP Purchases 118,404 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Rock Springs Capital Management LP raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 10.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,222,182 shares of the biopharmaceutical company's stock after purchasing an additional 118,404 shares during the quarter. Rock Springs Capital Management LP owned 1.84% of Celldex Therapeutics worth $30,885,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its position in shares of Celldex Therapeutics by 215.7% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 878 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics in the 4th quarter worth $81,000. KBC Group NV raised its stake in shares of Celldex Therapeutics by 79.1% in the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 2,705 shares in the last quarter. Finally, Aristides Capital LLC purchased a new stake in shares of Celldex Therapeutics during the fourth quarter valued at $202,000.

Wall Street Analysts Forecast Growth

CLDX has been the subject of a number of recent analyst reports. The Goldman Sachs Group decreased their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Cantor Fitzgerald restated an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. Morgan Stanley assumed coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price objective for the company. Finally, UBS Group initiated coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $54.33.

Celldex Therapeutics Trading Down 0.1 %

Celldex Therapeutics stock traded down $0.01 during midday trading on Friday, hitting $19.57. The stock had a trading volume of 377,561 shares, compared to its average volume of 880,655. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The company has a market capitalization of $1.30 billion, a PE ratio of -7.61 and a beta of 1.59. The firm's fifty day moving average is $19.21 and its two-hundred day moving average is $23.53.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. As a group, equities research analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.